The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study

被引:13
作者
Kim, Young Won [1 ]
Park, Jinsung [2 ]
Chung, Hong [3 ]
Kim, Hong-Wook [4 ]
Kim, Hyung Joon [4 ]
Jung, Jae Hung [5 ]
Kim, Won Tae [1 ]
机构
[1] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 28644, South Korea
[2] Eulji Univ, Sch Med, Dept Urol, Daejeon, South Korea
[3] Konkuk Univ, Sch Med, Dept Urol, Chungju, South Korea
[4] Konyang Univ, Coll Med, Dept Urol, Daejeon, South Korea
[5] Yonsei Univ, Wonju Coll Med, Dept Urol, Wonju, South Korea
关键词
Nocturia; Adrenergic alpha-Antagonists; Prostatic Hyperplasia; URINARY-TRACT SYMPTOMS; DOUBLE-BLIND; SLEEP; DESMOPRESSIN; QUALITY; EFFICACY;
D O I
10.5213/inj.2015.19.3.190
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To investigate improvement in nocturia and nocturnal polyuria in nocturnal polyuria patients after silodosin administration by using a 3-day frequency volume chart. Methods: This was a prospective multicenter study. We enrolled nocturnal polyuria patients (nocturnal polyuria index [NPi] >0.33), aged >= 60 years, diagnosed with the 3-day frequency volume charts of patients with benign prostatic hyperplasia taking alpha-blockers. Of the 54 patients, 30 (55.6%) completed the study according to the study protocol (per-protocol group), and 24 dropped out (dropout group). Results: Of the 24 patients in the dropout group, 5 withdrew consent due to side effects or lack of efficacy, 7 were lost to follow-up at 4 weeks, 8 were lost to follow-up at 12 weeks, and 4 dropped out due to failure to complete 3-day frequency volume charts at 12 weeks. In the per-protocol group, there was significant improvement in the International Prostate Symptom Score (IPSS), especially question numbers 1, 3, 4, 5, 6, 7, and the quality of life question (P=0.001, P = 0.007, P<0.001, P=0.003, P=0.049, P<0.001, and P<0.001, respectively). The Leeds sleep evaluation questionnaire (LSEQ) score for the sleep question improved from 64.36 to 70.43 (P = 0.039). The NPi reduced from 0.4005 to 0.3573 (P =0.027); however, in many cases, there was no improvement in nocturnal polyuria itself. In intention-to-treat analysis, there were significant improvements in IPSS and LSEQ in 45 patients. Conclusions: In elderly nocturnal polyuria patients, silodosin monotherapy exhibits good efficacy in improving nocturia and nocturnal polyuria; however, the mean NPi was still >0.33. Considering the high dropout rate of our study due to no implementation of 3-day frequency volume charts, prospective and large-scale studies are needed to confirm our results.
引用
收藏
页码:190 / 196
页数:7
相关论文
共 50 条
  • [31] Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency-volume chart
    Kojima, Yoshiyuki
    Sasaki, Shoichi
    Imura, Makoto
    Kubota, Yasue
    Hayashi, Yutaro
    Kohri, Kenjiro
    NEUROUROLOGY AND URODYNAMICS, 2012, 31 (01) : 80 - 85
  • [32] Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study
    Marks, Leonard S.
    Gittelman, Marc C.
    Hill, Lawrence A.
    Volinn, Weining
    Hoel, Gary
    UROLOGY, 2009, 74 (06) : 1318 - 1322
  • [33] The effect of doxazosin, Finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia
    Johnson, Theodore M., II
    Burrows, Pamela K.
    Kusek, John W.
    Nyberg, Leroy M.
    Tenover, J. Lisa
    Lepor, Herbert
    Roehrborn, Claus G.
    JOURNAL OF UROLOGY, 2007, 178 (05) : 2045 - 2050
  • [34] Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study
    Ichihara, Koji
    Masumori, Naoya
    Iwasawa, Akihiko
    Taguchi, Keisuke
    Yamaguchi, Yasuhiro
    Nishimura, Masahiro
    Sasamura, Hiroto
    Suzuki, Nobukazu
    Haga, Kazunori
    Miyao, Noriomi
    Hirose, Takaoki
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (10) : 849 - 854
  • [35] Prognostic factors for the efficacy of silodosin in the treatment of symptomatic Benign Prostatic Hyperplasia. Subanalysis of the URAL study
    Salinas-Casado, Jesus
    Virseda-Chamorro, Miguel
    Mendez-Rubio, Santiago
    Lujan-Galan, Marcos
    Esteban-Fuertes, Manuel
    Moreno-Sierra, Jesus
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (09): : 637 - 645
  • [36] Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates
    Capitanio, U.
    Salonia, A.
    Briganti, A.
    Montorsi, F.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (06) : 544 - 551
  • [37] Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study
    Asplund, R
    Sundberg, B
    Bengtsson, P
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (05): : 642 - 646
  • [38] The Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia with α-Blockers: Focus on Silodosin
    Fonseca, Julio
    da Silva, Carlos Martins
    CLINICAL DRUG INVESTIGATION, 2015, 35 : S7 - S18
  • [39] Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia
    Kawahara, Takashi
    Morita, Satoshi
    Ito, Hiroki
    Terao, Hideyuki
    Sakata, Ryoko
    Ishiguro, Hitoshi
    Tanaka, Katsuyuki
    Miyamoto, Hiroshi
    Matsuzaki, Junichi
    Kubota, Yoshinobu
    Uemura, Hiroji
    BMC UROLOGY, 2013, 13
  • [40] New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review
    Albisinni, Simone
    Aoun, Fouad
    Roumeguere, Thierry
    Porpiglia, Francesco
    Tubaro, Andrea
    De Nunzio, Cosimo
    MINERVA UROLOGICA E NEFROLOGICA, 2017, 69 (02) : 119 - 132